Disruptive Technologies and Emerging Trends Drive Life Science Transformation

USA - English

• India - English

MOUNTAIN VIEW, Calif., June 7, 2016 /PRNewswire/ -- Across Life Sciences, disruptive technologies and behavioural shifts are driving the transformation of business models, while emerging trends are creating growth opportunities throughout the industry. To take advantage of these opportunities and maintain a competitive advantage, companies must fully understand areas outside their expertise. Corporations failing to capitalize on opportunities will be late entrants to a market and lose out on the market share.

New analysis from Frost & Sullivan, 2016 Global Life Sciences Predictions (http://utm.io/256547), finds disruptive technologies and emerging trends will create growth opportunities for research tools, clinical diagnostics and pharmaceuticals.

If you are interested in more information, please contact Kayla Belcher, Corporate Communications, at [email protected].

Through growth opportunities, the Life Sciences industry will experience:

• Lucrative merger and acquisition opportunities in the Molecular Point of Care Testing (POCT) market
• Explosive growth in the Immunotherapies market
• A rapid adoption of CRISPR/Cas9 technologies
• Better defined regulatory pathways that will boost the Biosimilars Market
• A hybrid of business models for business intelligence embedded in clinical trials

"Emerging business models, such as Precision Medicine, NGS Informatics Tools & Services and Contract Development and Manufacturing Organization (CDMO) have enabled a paradigm shift from broad therapies to targeted therapies, transforming the clinical practice and treatment outcomes," said Frost & Sullivan Transformational Health Research Manager Sangeetha Prabakaran. "A better understanding of disease heterogeneity and identification of novel targets will foster collaboration between pharmaceutical companies, diagnostic manufacturers, payers and providers to develop new products and services."

Furthermore, the Life Sciences industry is expected to advance with the integration of multi-disciplinary capabilities in biology, chemistry and computational power, which a company can leverage to develop new solutions to treat complex diseases. This will create new growth opportunities, enabling companies to maximize product quality at the lowest cost.

"Shifting payment business models will determine who pays for healthcare services; it will be challenging to monetize innovative therapeutics, biosimilars and molecular diagnostics to align with value-based care models," noted Frost & Sullivan Transformational Health Global Vice President Nitin Naik.

For future endeavours, CEOs should closely watch companies Foundation Medicine and Rain Dance Technologies; research tools companies Eagle Genomics and DNA Nexus; pharmaceutical companies Actavis and Innovio; and CDMOs Patheon and Catalent.

Survive and Thrive in an Unpredictable Future! Schedule a Growth Strategy Dialog with the Life Sciences Global Team to discuss your strategic growth development and discover growth opportunities impacting your business, here: http://ww2.frost.com/consulting/.

2016 Global Life Sciences Predictions is part of the Life Sciences Growth Partnership Service program. Frost & Sullivan's related studies include: 2015 Global Laboratory Product Purchasing Trends, Industry Financial Review of the Global Laboratory Research Tools Market, United States Liquid Handling Market, and Global Next-generation Sequencing Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

• The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
• The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

2016 Global Life Sciences Predictions

Contact:
Kayla Belcher
Corporate Communications – North America
P: 210.247.2450
F: 210.348.1003
E: [email protected]

http://www.frost.com

Logo - http://photos.prnewswire.com/prnh/20160606/375903LOGO

SOURCE Frost & Sullivan

Related Links

http://www.frost.com